Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Asset Writedowns and Impairment (2023 - 2025)

Puma Biotechnology (PBYI) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 300.0% year-over-year to $400000.0, compared with a TTM value of -$300000.0 through Sep 2025, down 292.31%, and an annual FY2023 reading of $881000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $400000.0 for Q4 2025 at Puma Biotechnology, up from -$251000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.0 million in Q4 2021 and bottomed at -$362000.0 in Q2 2025.
  • Average Asset Writedowns and Impairment over 4 years is $169727.3, with a median of $111000.0 recorded in 2023.
  • The sharpest move saw Asset Writedowns and Impairment tumbled 140.0% in 2024, then surged 300.0% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $1.0 million in 2021, then tumbled by 74.4% to $256000.0 in 2023, then plummeted by 60.94% to $100000.0 in 2024, then soared by 300.0% to $400000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for PBYI at $400000.0 in Q4 2025, -$251000.0 in Q3 2025, and -$362000.0 in Q2 2025.